3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 4
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
NETWORK
1
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
28
Neoplasm Metastasis
6
Recurrence
5
Breast Neoplasms
4
Stomach Neoplasms
3
Prostate Cancer Metastatic
3
Neoplastic Cells, Circulating
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Penile Neoplasms
1
Nonseminomatous germ cell tumor
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lung Neoplasms
1
Liposarcoma
1
Hormone-Resistant Prostate Cancer
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Diarrhea
1
Interventions
enzalutamide
4
cabazitaxel
3
Docetaxel
3
Prednisone
2
talazoparib
1
rucaparib
1
pembrolizumab
1
olaparib
1
Zuclomiphene
1
XRP6258
1
Standard of Care
1
Radiosurgery
1
Positron Emission Tomography Computed Tomography
1
LY3023414
1
Injections
1
Carboplatin
1
Abituzumab
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Prostate Cancer Metastatic
×
cabazitaxel
×
Clear all
NCT05563558
2024-06-11
PEAPOD_FOS
Fundacion Oncosur
Phase 2
Recruiting
42 enrolled
NCT02379390
2019-06-21
PRIMCAB
Sanofi
Phase 2
Terminated
8 enrolled
8 charts
NCT01718353
2017-11-20
TAXYNERGY
Sanofi
Phase 2
Completed
63 enrolled
13 charts